Home › Diffuse groot-B-cel lymfoom › Tennessee › Nashville
Diffuse groot-B-cel lymfoom klinische studies in Nashville, TN
15 studies voor Diffuse groot-B-cel lymfoom zoeken deelnemers op locaties in en rond Nashville (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruterenFase 2
- Vanderbilt University Medical Center, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruterenFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruterenFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RekruterenFase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruterenFase 2
- SCRI Oncology Partners ( Site 7002), Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruterenFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RekruterenFase 2
- Tennessee Oncology, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruterenFase 1/2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruterenFase 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruterenFase 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
RekruterenFase 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- Tennessee Oncology, Nashville
Diffuse groot-B-cel lymfoom studies in andere steden
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Andere studies in Nashville
- Niet-kleincellige longkanker97 studies
- Borstkanker80 studies
- Metastatische kanker70 studies
- Colorectale kanker69 studies
- Kanker (alle vormen)65 studies
- Eierstokkanker49 studies
- Prostaatkanker42 studies
- Longkanker40 studies
- Plaveiselcelcarcinoom van hoofd en hals39 studies
- Aldermeesklierkanker39 studies
- Endometriumkanker38 studies
- Melanoom33 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.